Around 85 studies are investigating some form of neurological disorder ranging from the application of FDA-approved PDE drugs in different neurological scenarios to brand new Phase I trials to determine safety and tolerability of PDEs in AD, stroke and HD. Here, ALDH7A1 is linked to Alzheimer disease.